American Society of Hematology

Figure 3.

$One- and two-way sensitivity analyses. (A) One-way sensitivity analysis of the cost of CAR-T when second-line CAR-T is compared with SOC in primary refractory/early relapse patients. In this analysis, we vary the cost-of CAR-T while keeping other parameters constant and show that second-line CAR-T is cost-effective if it costs less than $972 061 (green dotted lines) at a WTP of $150 000. (B) Two-way sensitivity analysis of the 5-year EFS of second-line CAR-T and the cost of CAR-T. In this analysis, we vary the 5-year EFS of second-line CAR-T and the cost of CAR-T simultaneously while keeping other parameters constant. The area shaded blue represents the scenarios in which second-line CAR-T is the cost-effective strategy at a WTP of $150 000. In contrast, the area shaded red represents the scenarios in which second-line CAR-T is no longer the cost-effective strategy. (C) One-way sensitivity analysis of the 5-year EFS with second-line CAR-T therapy when second-line CAR-T is compared with SOC therapy in primary refractory/early relapse patients. In this analysis, we vary the 5-year EFS with second-line CAR-T while keeping other parameters constant and show that second-line CAR-T is cost-effective if it has a 5-year EFS of 26.4% or higher (green dotted lines) at a WTP of $150 000. (D) Two-way sensitivity analysis of the 5-year EFS of second-line CAR-T and the 5-year EFS with SOC therapy. In this analysis, we simultaneously vary the 5-year EFS of second-line CAR-T and the 5-year EFS of SOC therapy while keeping other parameters constant. The area shaded blue represents the scenarios in which second-line CAR-T is the cost-effective strategy at a WTP of $150 000. In contrast, the areas shaded red represents the scenarios in which second-line CAR-T is no longer the cost-effective strategy.$

One- and two-way sensitivity analyses. (A) One-way sensitivity analysis of the cost of CAR-T when second-line CAR-T is compared with SOC in primary refractory/early relapse patients. In this analysis, we vary the cost-of CAR-T while keeping other parameters constant and show that second-line CAR-T is cost-effective if it costs less than $972 061 (green dotted lines) at a WTP of $150 000. (B) Two-way sensitivity analysis of the 5-year EFS of second-line CAR-T and the cost of CAR-T. In this analysis, we vary the 5-year EFS of second-line CAR-T and the cost of CAR-T simultaneously while keeping other parameters constant. The area shaded blue represents the scenarios in which second-line CAR-T is the cost-effective strategy at a WTP of $150 000. In contrast, the area shaded red represents the scenarios in which second-line CAR-T is no longer the cost-effective strategy. (C) One-way sensitivity analysis of the 5-year EFS with second-line CAR-T therapy when second-line CAR-T is compared with SOC therapy in primary refractory/early relapse patients. In this analysis, we vary the 5-year EFS with second-line CAR-T while keeping other parameters constant and show that second-line CAR-T is cost-effective if it has a 5-year EFS of 26.4% or higher (green dotted lines) at a WTP of $150 000. (D) Two-way sensitivity analysis of the 5-year EFS of second-line CAR-T and the 5-year EFS with SOC therapy. In this analysis, we simultaneously vary the 5-year EFS of second-line CAR-T and the 5-year EFS of SOC therapy while keeping other parameters constant. The area shaded blue represents the scenarios in which second-line CAR-T is the cost-effective strategy at a WTP of $150 000. In contrast, the areas shaded red represents the scenarios in which second-line CAR-T is no longer the cost-effective strategy.

This Feature Is Available To Subscribers Only